Ronald Blue Trust, Inc. Madrigal Pharmaceuticals, Inc. Transaction History
Ronald Blue Trust, Inc.
- $8.16 Billion
- Q4 2024
A detailed history of Ronald Blue Trust, Inc. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 6 shares of MDGL stock, worth $1,948. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6
Previous 7
14.29%
Holding current value
$1,948
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding MDGL
# of Institutions
294Shares Held
22MCall Options Held
819KPut Options Held
640K-
Janus Henderson Group PLC London, X02.48MShares$805 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$663 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$659 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$647 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$641 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.55B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...